This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kinoshita, H. Articles by Jarrard, D. F. Search for Related Content PubMed PubMed Citation Articles by Kinoshita, H. Articles by Jarrard, D. F.

Methylation of the Androgen Receptor Minimal Promoter Silences Transcription in Human Prostate Cancer¹

Department of Surgery, Sections of Urology [H. K., Y. S., C. S., D. F. J.] and Pathology [A. C., A. F.], University of Wisconsin Medical School, Environmental Toxicology [C. R. R., D. F. J.], and University of Wisconsin Comprehensive Cancer Center [L. F. M., C. C., C. R. R., D. F. J.], Madison, Wisconsin 53792, and the Brady Urological Institute, Johns Hopkins Hospital, Baltimore, Maryland 21287 [G. S. B.]

Advanced hormone-independent prostate cancer is characterized by a significant loss of androgen receptor (AR) expression in 20–30% of the tumors. The transcriptional block underlying this phenomenon is not known, but we have proposed that methylation of CpG sites in the AR promoter may reversibly inactivate transcription of the AR (D. F. Jarrard et al., Cancer Res., 58: 5310–5314, 1998). In this study, detailed methylation analysis using bisulfite sequencing was performed on a series of AR expression-positive and -negative prostate cancer cells. We found that methylation of several consensus sequences in the AR promoter (from -131 to -121 and +44 to +54) are tightly linked to the loss of AR expression in metastatic hormone-independent prostate cancer cell lines. These consensus sites of methylation correlate with the minimal promoter region critical for AR transcription. In human tissues, no methylation was demonstrated in normal or primary prostate cancers that express the AR. Four of 15 tumors obtained from men who had died from hormone-independent prostate cancer demonstrated a significant loss of AR expression immunohistochemically and two (50%) of these AR-negative tumors contained AR methylation. We conclude that the AR promoter contains specific CpG methylation hot spots that are markers for gene silencing. Furthermore, AR methylation may represent a phenotype important in the development of hormone independence in a subset of advanced prostate cancer in which AR expression is lost. The finding of AR methylation also represents the first report of aberrant methylation on an X-linked gene associated with a somatic male cancer.

This article has been cited by other articles:

				S. Kaulfuss, M. Grzmil, B. Hemmerlein, P. Thelen, S. Schweyer, J. Neesen, L. Bubendorf, A. G. Glass, H. Jarry, B. Auber, et al. Leupaxin, a Novel Coactivator of the Androgen Receptor, Is Expressed in Prostate Cancer and Plays a Role in Adhesion and Invasion of Prostate Carcinoma Cells Mol. Endocrinol., July 1, 2008; 22(7): 1606 - 1621. [Abstract] [Full Text] [PDF]

				B. Kwabi-Addo, W. Chung, L. Shen, M. Ittmann, T. Wheeler, J. Jelinek, and J.-P. J. Issa Age-Related DNA Methylation Changes in Normal Human Prostate Tissues Clin. Cancer Res., July 1, 2007; 13(13): 3796 - 3802. [Abstract] [Full Text] [PDF]

				J. N. Davis, K. J. Wojno, S. Daignault, M. D. Hofer, R. Kuefer, M. A. Rubin, and M. L. Day Elevated E2F1 Inhibits Transcription of the Androgen Receptor in Metastatic Hormone-Resistant Prostate Cancer Cancer Res., December 15, 2006; 66(24): 11897 - 11906. [Abstract] [Full Text] [PDF]

				A. S Perry, R. Foley, K. Woodson, and M. Lawler The emerging roles of DNA methylation in the clinical management of prostate cancer. Endocr. Relat. Cancer, June 1, 2006; 13(2): 357 - 377. [Abstract] [Full Text] [PDF]

				J. D. Debes, B. Comuzzi, L. J. Schmidt, S. M. Dehm, Z. Culig, and D. J. Tindall p300 Regulates Androgen Receptor-Independent Expression of Prostate-Specific Antigen in Prostate Cancer Cells Treated Chronically with Interleukin-6 Cancer Res., July 1, 2005; 65(13): 5965 - 5973. [Abstract] [Full Text] [PDF]

				L.-C. Li, P. R. Carroll, and R. Dahiya Epigenetic Changes in Prostate Cancer: Implication for Diagnosis and Treatment J Natl Cancer Inst, January 19, 2005; 97(2): 103 - 115. [Abstract] [Full Text] [PDF]

				J. Gilbert, S. D. Gore, J. G. Herman, and M. A. Carducci The Clinical Application of Targeting Cancer through Histone Acetylation and Hypomethylation Clin. Cancer Res., July 15, 2004; 10(14): 4589 - 4596. [Abstract] [Full Text] [PDF]

				H. Yang, C.-M. Chen, P. Yan, T. H-M. Huang, H. Shi, M. Burger, I. Nimmrich, S. Maier, K. Berlin, and C. W. Caldwell The Androgen Receptor Gene is Preferentially Hypermethylated in Follicular Non-Hodgkin's Lymphomas Clin. Cancer Res., September 15, 2003; 9(11): 4034 - 4042. [Abstract] [Full Text] [PDF]

				D. K. Lee and C. Chang Expression and Degradation of Androgen Receptor: Mechanism and Clinical Implication J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4043 - 4054. [Abstract] [Full Text] [PDF]

				C. G. Tepper, D. L. Boucher, P. E. Ryan, A.-H. Ma, L. Xia, L.-F. Lee, T. G. Pretlow, and H.-J. Kung Characterization of a Novel Androgen Receptor Mutation in a Relapsed CWR22 Prostate Cancer Xenograft and Cell Line Cancer Res., November 15, 2002; 62(22): 6606 - 6614. [Abstract] [Full Text] [PDF]

				A. Kerjean, A. Vieillefond, N. Thiounn, M. Sibony, M. Jeanpierre, and P. Jouannet Bisulfite genomic sequencing of microdissected cells Nucleic Acids Res., November 1, 2001; 29(21): e106 - e106. [Abstract] [Full Text] [PDF]

				M. J. Linja, K. J. Savinainen, O. R. Saramäki, T. L. J. Tammela, R. L. Vessella, and T. Visakorpi Amplification and Overexpression of Androgen Receptor Gene in Hormone-Refractory Prostate Cancer Cancer Res., May 1, 2001; 61(9): 3550 - 3555. [Abstract] [Full Text]